secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2023-09-14T23:59:59+00:00
Accession:  0001104659-23-100787
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute reports FY2023 net loss of $51.8M; Phase 3 for RZ358 to start Q4 2023
------------------------------------------------------------------------------

- Cash and equivalents $16.0M, marketable securities $102.3M as of June 30, 2023.
- Full year net loss $51.8M vs $41.1M prior year; R&D spend $43.8M (up from $32.5M).
- Phase 3 sunRIZE study for RZ358 in congenital HI to initiate Q4 2023; topline data H1 2025.
- Phase 2 study of RZ402 for diabetic macular edema ongoing; results expected Q1 2024.
- Q4 net loss $12.7M vs $9.4M in prior year quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465923100787/0001104659-23-100787-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465923100787/tm2325841d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-100787

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer